PMID- 32963505
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1559-3258 (Print)
IS  - 1559-3258 (Electronic)
IS  - 1559-3258 (Linking)
VI  - 18
IP  - 3
DP  - 2020 Jul-Sep
TI  - Beneficial Effects of Glycyrrhizin in Chronic Periodontitis Through the 
      Inhibition of Inflammatory Response.
PG  - 1559325820952660
LID - 10.1177/1559325820952660 [doi]
LID - 1559325820952660
AB  - Elevated inflammatory cytokines and high mobility group box 1 (HMGB1) production 
      are associated with chronic periodontitis (CP). Glycyrrhizin is the major 
      constituent of Glycyrrhiza glabra. L. (Fabaceae) root with anti-inflammation 
      activities. This study evaluated the effects of glycyrrhizin on CP. TNF-alpha-treated 
      human periodontal ligament stem cell (hPDLSC) model was established, and was 
      administrated with 1, 2 or 5 mM glycyrrhizin for 24 h. After treatment, the 
      expression of HMGB1and inflammatory cytokines was monitored. Significantly 
      increased HMGB1 (median: 5646.4, range: 1918.2-8233.7 vs median: 204.5, range: 
      98.7-283.6, pg/mL), TNF-alpha (median: 345.5, range: 161.0-567.9 vs median: 93.5, 
      range: 58.1-159.3, pg/mL), IL-1beta (median: 2014.6, range: 209.5-4308.1 vs median: 
      224.5, range: 48.8-335.8, pg/mL) and IL-6 (median: 1223.6, range: 398.2-2183.8 vs 
      median: 240.4, range: 105.2-400.5, pg/mL) were detected in gingival crevicular 
      fluid from CP patients. Glycyrrhizin significantly prevented TNF-alpha-induced 
      expression of HMGB1 (691.5 +/- 136.4 vs 142.8 +/- 57.3 pg/mL), IL-6 (388.1 +/- 85.2 vs 
      189.4 +/- 61.2 pg/mL) and IL-1beta (176.3 +/- 47.2 vs 53.9 +/- 25.7 pg/mL) in hPDLSC. In 
      CP rats, glycyrrhizin significantly decreased HMGB1 (5795.6 +/- 1121.5 vs 586.4 +/- 
      436.8 pg/mL), TNF-alpha (421.8 +/- 93.7 vs 87.9 +/- 21.6 pg/mL), IL-6 (1423.8 +/- 235.2 vs 
      622.6 +/- 176.1 pg/mL) and IL-1beta (1562.8 +/- 334.3 vs 733.5 +/- 265.1 pg/mL) in 
      gingival crevicular fluid. Glycyrrhizin suppresses inflammatory activities in CP 
      rats and represents a promising molecule for controlling CP.
CI  - (c) The Author(s) 2020.
FAU - Sun, Yaru
AU  - Sun Y
AUID- ORCID: 0000-0003-4112-5646
AD  - Department of Stomatology Clinic, Cangzhou Central Hospital, Cangzhou, Hebei, 
      China.
FAU - Zhao, Binghui
AU  - Zhao B
AD  - Department of Anorectal Surgery, Cangzhou Central Hospital, Cangzhou, Hebei, 
      China.
FAU - Li, Zhaobao
AU  - Li Z
AD  - Department of Stomatology Clinic, Cangzhou Central Hospital, Cangzhou, Hebei, 
      China.
FAU - Wei, Jianming
AU  - Wei J
AD  - Department of Stomatology Clinic, Cangzhou Central Hospital, Cangzhou, Hebei, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20200910
PL  - United States
TA  - Dose Response
JT  - Dose-response : a publication of International Hormesis Society
JID - 101308899
PMC - PMC7488895
OTO - NOTNLM
OT  - IL-1beta
OT  - IL-6
OT  - TNF-alpha
OT  - gingival crevicular fluid
OT  - gingival tissues
OT  - inflammation
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:01
PMCR- 2020/09/10
CRDT- 2020/09/23 06:34
PHST- 2020/09/23 06:34 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:01 [medline]
PHST- 2020/09/10 00:00 [pmc-release]
AID - 10.1177_1559325820952660 [pii]
AID - 10.1177/1559325820952660 [doi]
PST - epublish
SO  - Dose Response. 2020 Sep 10;18(3):1559325820952660. doi: 10.1177/1559325820952660. 
      eCollection 2020 Jul-Sep.